Enoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiency

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 769-772

  Malik, Ahmed ^a   Capling, Richard ^a   Bastani, Bahar ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Chronic kidney disease; Enoxaparin; Heparin; Retroperitoneal hematoma

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CEFTRIAXONE; CLONIDINE; CLOPIDOGREL; CREATININE; DIPYRIDAMOLE; ENOXAPARIN; FLUTICASONE PROPIONATE; FUROSEMIDE; HEPARIN; HYDRALAZINE; INSULIN; LEVOFLOXACIN; LOW MOLECULAR WEIGHT HEPARIN; MONTELUKAST; NIFEDIPINE; PANTOPRAZOLE; SIMVASTATIN; WARFARIN;

ABDOMINAL PAIN; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; EMBOLISM; ERYTHROCYTE CONCENTRATE; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOCRIT; HUMAN; KIDNEY FAILURE; OBESITY; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; RETROPERITONEAL HEMATOMA; RETROPERITONEAL HEMORRHAGE;

AGED; ANTICOAGULANTS; ENOXAPARIN; FEMALE; HEMATOMA; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RETROPERITONEAL SPACE;

EID: 18044372816     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.769.63596     Document Type: Article

References (24)

1. Cohen M, Demers C, Gurfinkel EP, et al. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group: a comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
2. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-18.
3. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized controlled trials. Ann Intern Med 1999;130:800-9.
4. Farooq V, Hegarty J, Chandrasaker T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004;43:531-7.
5. Hirsch J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
6. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-98.
7. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infraction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
8. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review of patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-5.
9. Melde SL. Enoxaparin-induced retroperitoneal hematoma. Ann Pharmacother 2003;37:822-4.
10. Dabney A, Bastani B. Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: a report of two cases. Intensive Care Med 2001;27:1954-7.
11. Shullo MA, Rose ML, Vivas C, et al. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy 2002;22:184-7.
12. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001;67:54-6.
13. Chan-Tack KM. Fatal spontaneous retroperitoneal hematoma secondary to enoxaparin. South Med J 2003;96:58-60.
14. Power GE, Rogers P. Retroperitoneal hematoma associated with low molecular weight heparin. Anaesth Intensive Care 2002;30:665-7.
15. Bang CJ, Riedel B, Talstad I, Berstad A. Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans. Scand J Gastroenterol 1992;27:489-99.
16. Goudable C, Ton That H, Damani A, et al. Low molecular weight heparin half-life is prolonged in hemodialysed patients. Thromb Res 1986;43:1-5.
17. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991;63:385-90.
18. Becker RC, Spencer FA, Gibson M, et al, for the TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST segment elevation in acute coronary syndromes. Am Heart J 2002;143:753-9.
19. Aventis Pharmaceuticals Inc. Lovenox (enoxaparin) package insert. Bridgewater, NJ; December 2003.
20. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001;21:218-34.
21. Mrug M, Mishra PV, Lusane HC, Cunningham JM, Alpert MA. Hemothorax and retroperitoneal hematoma after coagulation with enoxaparin. South Med J 2002;95:936-7.
22. Vadnerker A, Brensilver JM. Enoxaparin-associated spontaneous retroperitoneal hematoma in elderly patients with impaired creatinine clearance: a report of two cases. J Am Geriatr Soc 2004;53(3):477-9.
23. Narnajo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
24. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004;148:582-9.